Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XP23829 · 1 trial · 1 indication
The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The minimum possible score on this scale is '0', while the maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of subject.
| Arm | Type | Description |
|---|---|---|
| XP23829 400 mg QD (once daily) | EXPERIMENTAL | After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period |
| XP23829 800 mg QD | EXPERIMENTAL | After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period |
| XP23829 400 mg BID (twice daily) | EXPERIMENTAL | After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period |
| Placebo | PLACEBO_COMPARATOR | After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks |
| Name | Type | Description |
|---|---|---|
| XP23829 400 mg QD | DRUG | active dose 1 |
| XP 23829 800 mg QD | DRUG | active dose 2 |
| XP23829 400 mg BID | DRUG | active dose 3 |
| Placebo | DRUG | control |
Inclusion Criteria: 1. Male and female subjects, age ≥ 18. 2. Stable, moderate-to-severe plaque-type psoriasis diagnosed for at least 6 months prior to randomization (no morphology changes or significant flares of disease activity in the last 6 months in the opinion of the investigator). 3. Severit...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
XP23829 is an investigational small molecule drug being developed by Dr. Reddy's Laboratories Ltd for the treatment of moderate-to-severe chronic plaque-type psoriasis, a skin condition. It is a Phase 2 clinical candidate and has not been approved by the FDA. The drug is also referred to as XP23829 400 mg QD.
XP23829 is being studied for the treatment of moderate-to-severe chronic plaque-type psoriasis. Psoriasis is a chronic inflammatory skin disease characterized by raised, scaly plaques. The drug is in Phase 2 development and is not yet approved for any indication.
XP23829 is being developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. The company is responsible for the clinical development of this small molecule candidate for psoriasis.
XP23829 is in Phase 2 clinical development. It has completed one Phase 2 trial in patients with moderate-to-severe chronic plaque-type psoriasis. The drug is investigational and has not received FDA approval.
XP23829 has been evaluated in one completed Phase 2 trial, NCT02173301, titled "A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis." The trial enrolled 200 participants in the United States and was randomized, double-blind, and placebo-controlled.